Alpha1-acid glycoprotein concentration and protein binding in trauma

Area of Science:

• Pharmacology
• Clinical Chemistry
• Biochemistry

Background:

• Alpha 1-Acid glycoprotein (AAG) is a key plasma protein involved in drug binding.
• Understanding AAG concentration changes is crucial for interpreting drug pharmacokinetics, especially in trauma patients.

Purpose of the Study:

• To investigate the dynamic changes in Alpha 1-Acid glycoprotein (AAG) concentrations in trauma patients.
• To determine the correlation between AAG levels and drug protein binding in trauma and healthy subjects.

Main Methods:

• Serum AAG concentrations were measured serially in trauma patients and healthy controls over 3 weeks.
• Protein binding of lidocaine was assessed, and the binding ratio (bound/free concentration) was calculated.
• Statistical analysis, including correlation coefficients, was used to evaluate the relationship between AAG levels and binding ratios.

Main Results:

• Trauma patients exhibited a marked increase in AAG concentrations, peaking at 243 mg/dl between days 10-14.
• Healthy subjects maintained a stable mean AAG concentration of 70 mg/dl.
• A strong positive correlation was observed between AAG concentration and the binding ratio in both patient and control groups (r=0.92 and r=0.84, respectively).

Conclusions:

• Elevated AAG levels in trauma patients significantly enhance drug binding, altering the free fraction of medications.
• These AAG-mediated changes in protein binding can substantially impact drug concentration-response relationships in critically ill patients.
• Monitoring AAG levels may be essential for optimizing pharmacotherapy in trauma care.